The prognostic significance of FBXO2 expression in colorectal cancer

• Published in: International journal of clinical and experimental pathology Vol. 11; no. 10; pp. 5054 - 5062
• Main Authors: Wei, Xinying, Bu, Juyuan, Mo, Xiangqiong, Lv, Baojun, Wang, Xiao, Hou, Bingzong
• Format: Journal Article
• Language: English
• Published: United States e-Century Publishing Corporation 01.01.2018
• Subjects: Original; immunohistochemistry; Ki67; N-cadherin; FBXO2; Colorectal cancer
• ISSN: 1936-2625

Colorectal cancer is the third most frequently diagnosed malignancy, and the prognosis at advanced tumor stages remains poor. FBXO2, a member of the F-box protein family, is a cytoplasmic protein and an ubiquitin ligase. The aim of this study was to investigate the role of FBXO2 in colorectal cancer. The expression levels of Ki67, N-cadherin and FBXO2 were detected in 195 pairs of primary CRC tissues using immunohistochemistry (IHC). The associations among Ki67, N-cadherin, and FBXO2 expression, as well as the clinicopathological parameters, were analyzed. Survival curves were calculated with the Kaplan-Meier method. Univariate and multivariate analyses were performed to explore the prognostic significance of Ki67, N-cadherin, and FBXO2 expression. We found that the positive rates of Ki67, N-cadherin and FBXO2 expression in CRC tissue samples were 55.9%, 65.1%, 62.6%, respectively. The high expression levels of Ki67 and N-cadherin were significantly correlated with CRC size (P = 0.01) and metastasis (P = 0.01), respectively. The high expression level of FBXO2 was significantly correlated with CRC metastasis (P = 0.04) and AJCC stage (P = 0.029). A Cox regression analysis revealed that FBXO2 is an independent prognostic factor for CRC patients (HR 1.817, 95% CI 1.106-2.983, P = 0.018). FBXO2 may serve as a biomarker for metastasis and a reliable predictor for poor prognosis in CRC patients.